Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3CNS 1Breast 1

Conditions

Pituitary Diseases 3Pituitary ACTH Hypersecretion 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Hirsutism 2Choristoma 2Adrenal Cortex Neoplasms 2

Interventions

Everolimus 8lanreotide 7Octreotide 7lutetium Lu 177 dotatate 6pasireotide 5Thyrotropin Alfa 5Mitotane 4Etoposide 4Doxorubicin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Mifepristone 3Filgrastim 3Corlux 3Cisplatin 3Chemotherapy, Adjuvant 3Capecitabine 3Cabergoline 3vandetanib 2telotristat ethyl 2surufatinib 2ribociclib 2fluorodopa F 18 2cabozantinib 2Temozolomide 2Receptor-Like Protein Tyrosine Phosphatases, Class 2 2Lutetium-177 2Lutetium 2Leucovorin 2Iodine-131 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Mifepristone × Endocrine × Clear all
NCT00936741 2014-04-02

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
30 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT01371565 2014-03-18

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
4 enrolled 7 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT00569582 2013-08-22

SEISMIC

Corcept Therapeutics

Phase 3 Completed
50 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡